Evidence map›Paper›PMID 38867530›Full record

ReviewCurrent HIV research2024

Pill Burden: A Major Barrier to HAART Adherence and Fixed Dose Combinations (FDCS) as its Solution - A Mini-Review.

Mugisa Simon, Ssebaduka Derrick, Sreya Kosanam, Rajeshwari Pasupula

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current HIV research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mugisa SimonDepartment of Pharmacology, College of Pharmacy, Koneru Lakshmaiah Education Foundation, KL Deemed to be University, Green Fields, Vaddeswaram, Andhra Pradesh, India.
Ssebaduka DerrickDepartment of Pharmacology, College of Pharmacy, Koneru Lakshmaiah Education Foundation, KL Deemed to be University, Green Fields, Vaddeswaram, Andhra Pradesh, India.
Sreya KosanamDepartment of Pharmacy Practice, Sandip Institute of Pharmaceutical Sciences, Nashik, Maharashtra, India.ORCID 0000-0002-0645-5677
Rajeshwari PasupulaDepartment of Pharmacology, College of Pharmacy, Koneru Lakshmaiah Education Foundation, KL Deemed to be University, Green Fields, Vaddeswaram, Andhra Pradesh, India.ORCID 0000-0002-4782-3261

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV/ AIDS is a global pandemic, one of the most challenging; with no cure for the disease, various therapies available in the form of regimens as Highly Active Anti-Retroviral Therapy (HAART) or simply Anti-Retroviral Therapy (ART) are the only way to manage the disease. The Fixed Dose Combinations (FDCs) concept has been a well-recognised improvement in pharmacotherapy for the treatment of a variety of chronic maladies like hypertension, diabetes, HIV/AIDS, and several FDC products consisting of HIV drugs are approved. These single-tablet regimens have been essential in streamlining ART, lowering pill burden and increasing adherence. Adherence to HAART is the most vital factor to ensure medication success and virologic suppression. However, adherence is faced with several barriers including adverse effects of drugs, the complexity of ART, social-cultural factors, and pill burden among others. This writing reviews the concept of adherence to ART, and its barriers while stressing pill burden as a significant one which we suggest would be solved by using Fixed Dose Combinations (FDCs).

Indexed as

Anti-HIV AgentsAntiretroviral Therapy, Highly ActiveDrug CombinationsDrug MonitoringHIV InfectionsHumansAnti-HIV AgentsDrug CombinationsAdherenceanti-retroviral therapy morbidity.fixed-dose combinationHAARTHIVpill burden

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.